14 [124] N. M. Kaplan, “Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism,” Annals of Internal Medicine, vol. 66, no. 6, pp. 1079–1090, 1967. [125] A. M. Sinclair, C. G. Isles, I. Brown, H. Cameron, G. D. Murray, and J. W. Robertson, “Seconary hypertension in a blood pressure clinic,” Archives of Internal Medicine, vol. 147, no. 7, pp. 1289–1296, 1987. [126] R. W. Giﬀord Jr., “Evaluation of the hypertensive patient with emphasis on detecting curable causes,” Milbank Memorial Fund Quarterly, vol. 47, pp. 170–186, 1969. [127] G. S. Andersen, D. B. Toftdahl, J. O. Lund, S. Strandgaard, and P. E. Nielsen, “The incidence rate of phaeochromocytoma and Conn’s syndrome in Denmark, 1977–1981,” Journal of Human Hypertension, vol. 2, no. 3, pp. 187–189, 1988. [128] P. O. Lim, P. Rodgers, K. Cardale, A. D. Watson, and T. M. MacDonald, “Potentially high prevalence of primary aldosteronism in a primary-care population,” Lancet, vol. 353, no. 9146, article 40, 1999. [129] P. Mulatero, M. Stowasser, K. C. Loh et al., “Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from ﬁve continents,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 3, pp. 1045–1050, 2004. [130] C. E. Fardella, L. Mosso, C. Gomez-Sanchez et al., “Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical proﬁle, and molecular biology,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 5, pp. 1863–1867, 2000. [131] M. Stowasser, R. D. Gordon, T. G. Gunasekera et al., “High rate of detection of primary aldosteronism, including surgically treatable forms, after ’non-selective’ screening of hypertensive patients,” Journal of Hypertension, vol. 21, no. 11, pp. 2149–2157, 2003. [132] G. L. Schwartz and S. T. Turner, “Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity,” Clinical Chemistry, vol. 51, no. 2, pp. 386–394, 2005. [133] G. P. Rossi, G. Bernini, C. Caliumi et al., “A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients,” Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2293–2300, 2006. [134] L. Mosso, C. Carvajal, A. Gonzalez et al., “Primary aldoster- onism and hypertensive disease,” Hypertension, vol. 42, no. 2, pp. 161–165, 2003. [135] B. Strauch, T. Zelinka, M. Hampf, R. Bernhardt, and J. Widimsky Jr., “Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region,” Journal of Human Hypertension, vol. 17, no. 5, pp. 349–352, 2003. [136] M. Stowasser and R. D. Gordon, “Primary aldosteronism— careful investigation is essential and rewarding,” Molecular and Cellular Endocrinology, vol. 217, no. 1-2, pp. 33–39, 2004. [137] P. Mulatero, R. G. Dluhy, G. Giacchetti, M. Boscaro, F. Veglio, and P. M. Stewart, “Diagnosis of primary aldosteronism: from screening to subtype diﬀerentiation,” Trends in Endocrinology and Metabolism, vol. 16, no. 3, pp. 114–119, 2005. [138] D. A. Calhoun, M. K. Nishizaka, M. A. Zaman, R. B. Thakkar, and P. Weissman, “High prevalence of primary aldosteronism among black and white subjects with resistant hypertension,” Hypertension, vol. 40, pp. 892–896, 2002. International Journal of Hypertension [139] B. J. Gallay, S. Ahmad, L. Xu, B. Toivola, and R. C. Davidson, “Screening for primary hyperaldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio,” American Journal of Kidney Diseases, vol. 37, pp. 699–705, 2001. [140] I. K. Eide, P. A. Torjesen, A. Drolsum, A. Babovic, and N. P. Lilledahl, “Low-renin status in therapy-resistant hypertension: a clue to eﬃcient treatment,” Journal of Hypertension, vol. 22, no. 11, pp. 2217–2226, 2004. [141] N. Martell, M. Rodriguez-Cerrillo, D. E. Grobee et al., “High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension,” Blood Press, vol. 12, pp. 149–154, 2003. [142] G. E. Umpierrez, P. Cantey, D. Smiley et al., “Primary Aldos- teronism in diabetic subjects with resistant hypertension,” Diabetes Care, vol. 30, no. 7, pp. 1699–1703, 2007. [143] S. Douma, K. Petidis, M. Doumas et al., “Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study,” Lancet, vol. 371, no. 9628, pp. 1921–1926, 2008. [144] C. C. Gonzaga, K. K. Gaddam, M. I. Ahmed et al., “Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension,” Journal of Clinical Sleep Medicine, vol. 6, no. 4, pp. 363–368, 2010. [145] A. Di Murro, L. Petramala, D. Cotesta et al., “Renin- angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 11, no. 3, pp. 165–172, 2010. [146] D. A. Sica, “Endocrine causes of secondary hypertension,” Journal of Clinical Hypertension, vol. 10, no. 7, pp. 534–540, 2008. [147] A. Mazza, M. Armigliato, S. Zamboni et al., “Endocrine arte- rial hypertension: therapeutic approach in clinical practice,” Minerva Endocrinologica, vol. 33, no. 4, pp. 297–312, 2008. [148] J. Coresh, G. L. Wei, G. McQuillan et al., “Prevalence of high blood pressure and elevated serum creatinine level in the United States: ﬁndings from the third national health and nutrition examination survey (1988–1994),” Archives of Internal Medicine, vol. 161, no. 9, pp. 1207–1216, 2001. [149] G. Mancia, G. de Backer, A. Dominiczak et al., “2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” Journal of Hypertension, vol. 25, no. 6, pp. 1105–1187, 2007. [150] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003. [151] A. S. Levey, M. V. Rocco, S. Anderson et al., “K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease,” American Journal of Kidney Diseases, vol. 43, no. 5, pp. 1–290, 2004. [152] W. C. Cushman, C. E. Ford, J. A. Cutler et al., “Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attact trial (ALLHAT),” Journal of Clinical Hypertension, vol. 4, no. 6, pp. 393–404, 2002. [153] M. G. Saelen, L. K. Prøsch, H. Gudmundsdottir et al., “Controlling systolic blood pressure is diﬃcult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function,” Blood Pressure, vol. 14, no. 3, pp. 170–176, 2005.